JCS speaks with Lawrence Friedhoff, the Chief Development Officer of Axovant Sciences, about his involvement with the development of Donepezil, the most widely-used drug for the treatment of Alzheimer’s.
JCS speaks with Lawrence Friedhoff, the Chief Development Officer of Axovant Sciences, about his involvement with the development of Donepezil, the most widely-used drug for the treatment of Alzheimer’s.
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
